Institutional members access full text with Ovid®

Share this article on:

Rivastigmine in the Treatment of Hypersexuality in Alzheimer Disease

Canevelli, Marco MD; Talarico, Giuseppina MD, PhD; Tosto, Giuseppe MD; Troili, Fernanda; Lenzi, Gian Luigi MD; Bruno, Giuseppe MD, PhD

Alzheimer Disease & Associated Disorders: July-September 2013 - Volume 27 - Issue 3 - p 287–288
doi: 10.1097/WAD.0b013e31825c85ae
Case Report

Inappropriate sexual behaviors (ISB) represent uncommon and often misdiagnosed clinical disorders among patients with Alzheimer disease. So far, no randomized clinical trials regarding the treatment of ISB in demented people have been conducted, but available data from case series and isolated case reports suggest the efficacy of selective serotonin reuptake inhibitors (SSRIs), antipsychotics, antiandrogens, and H2-receptor antagonists. Controversial data exist on the therapeutic influence of cholinesterase inhibitors on sexual disorders. In the present article, we describe the case of an Alzheimer disease patient presenting hypersexuality, successfully treated with rivastigmine. Thus, we perform a revision of the existing literature regarding the therapeutical effect of cholinesterase inhibitors in the treatment of ISB.

Department of Neurology and Psychiatry, Memory Clinic, University “Sapienza,” Viale dell’Università, Rome, Italy

The authors declare no conflicts of interest.

Reprints: Marco Canevelli, MD, Department of Neurology and Psychiatry, Memory Clinic, University “Sapienza,” Viale dell’Università 30, Rome 00185, Italy (e-mail: marco.canevelli@gmail.com).

Received February 28, 2012

Accepted April 20, 2012

© 2013 by Lippincott Williams & Wilkins.